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Abstract 
 
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder 
characterized by arteriovenous malformations and hemorrhages. This vascular disease results 
mainly from mutations in 2 genes involved in the TGF-β pathway (ENG and ALK1) that are 
exclusively expressed by endothelial cells. The present study identified miR-27a and miR-205 
as two circulating miRNAs differentially expressed in HHT patients. The plasma levels of 
miR-27a are elevated while those of miR-205 are reduced in both HHT1 and HHT2 patients 
compared to healthy controls. The role of miR-205 in endothelial cells was further 
investigated. Our data indicates that miR-205 expression displaces the TGF-β balance towards 
the anti-angiogenic side by targeting Smad1 and Smad4. In line, overexpression of miR-205 
in endothelial cells reduces proliferation, migration and tube formation while its inhibition 
shows opposite effects. This study not only suggests that detection of circulating miRNA 
(miR-27a and miR-205) could help for the screening of HHT patients but also provides a 
functional link between the deregulated expression of miR-205 and the HHT phenotype 
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Introduction 
 
Hereditary hemorrhagic telangiectasia (HHT) or Rendu–Osler–Weber syndrome is an 
autosomal dominant vascular disorder characterized by recurrent nose bleeding telangiectases 
in mucosa and internal arteriovenous malformations (AMV- direct arterio-venous connections 
lacking intervening capillaries). AVMs that occur in the lungs, brain, or gastrointestinal tract 
can cause life-threatening complications secondary to either hemorrhagse or the shunting of 
blood through abnormal blood vessels. No cure for HHT has been found and there is a current 
need to find new effective drug treatments for the disease. HHT is diagnosed on clinical 
grounds. To be considered as an HHT patient, three or more of the following diagnostic 
criteria must be present: spontaneous-recurrent epistaxis, mucocutaneoustelangiectases, 
internal AVMs, and/or a first degree relative with HHT. The diagnosis is declared possible or 
suspected when two criteria are present and unlikely when they are fewer than two [1]. Since 
HHT is a clinically heterogeneous disorder, with symptoms differing even among the 
members of a same family, it is difficult to establish a proper diagnosis. 
There are two main types of HHT. Type 1 is due to mutations in the endoglin gene, 
encoding an accessory endothelial transforming growth factor-β (TGF-β) receptor. Type 2 is 
caused by mutations in ALK1 (ACVRL1; activin receptor-like kinase 1) gene, encoding a 
TGF-β type I receptor expressed in endothelial cells. In both, HHT1 and HHT2, the TGF-β 
signaling pathway of endothelial cells is affected [2]. TGFβ superfamily ligands mediate their 
effects through heteromeric complexes of type I and type II receptors. Upon ligand binding to 
type II receptor, the latter is activated and phosphorylates the TGF-β type I receptor, which in 
turn phosphorylates specific R (receptor-regulated)-Smads that can then interact with the Co 
(common-mediator)-Smad4 and translocates to the nucleus to regulate transcription of 
specific target genes, usually interacting with other transcription factors [3,4]. In endothelial 
cells, TGF-β1 can activate two distinct type I receptor/Smad signaling pathways with opposite 
effects on angiogenesis [5]. TGF-β1, in most cell types, predominantly signals via the type I 
receptor ALK5 leading to the activation of Smad2/3 and transcription of the corresponding 
target genes, such as PAI-1 (plasminogen activator inhibitor-1) which in endothelial cells is 
associated with cell quiescence. In addition in endothelial cells, TGFβ1 can also signal via 
ACVRL1/ALK1 which leads to phosphorylation of R-Smad1/5/8 with the consequent 
activation of targets distinct from ALK5, such as ID1 (inhibitor of DNA binding 1) which is 
associated with cell migration, proliferation and angiogenesis. 
MicroRNAs (miRNAs) are short (+/- 22 nucleotides long) non-coding RNAs that 
repress gene expression post-transcriptionally by targeting the 3’-untranslated region (3’UTR) 
of specific mRNAs [6]. MiRNAs play a major role in vascular biology [7-9] and “angio-
miRs” (miRNAs that stimulate or repress angiogenesis) have opened up a novel aspect for 
therapeutics associated with deregulated angiogenesis [10] and vascular diseases [11]. 
Recently, blood-based miRNA detection, measuring miRNAs in the plasma, protected from 
endogenous RNase activity included in exosomes or in association with proteins, has emerged 
as a promising diagnostic tool. 
In this study, we identified a circulating miRNA signature that could help identify 
HHT patients. We observed that levels of miR-27a are significantly higher while levels of 
miR-205 are significantly lower in plasma from HHT patients compared to healthy controls. 
The role of miR-27a in promoting angiogenesis was previously described [12] but the role of 
miR-205 in endothelial cells was unknown so far. We found that miR-205 reduces EC 
proliferation, migration and tube formation. In addition, we demonstrated that the expression 
of miR-205 affects TGF-β pathway, by targeting Smad1 and Smad4. This study is the first to 
establish a link between miRNA expression and the HHT disorder and paves the way for 
developing better diagnostic tools for HHT patient screening.  
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Results 
 
Circulating levels of miR-27a and miR-205 are altered in HHT patient plasma 
In order to identify specific biomarkers of HHT, we performed a miRNA expression 
profiling, using miRNA PCR panels (Exiqon) of plasma samples from HHT patients (2 HHT1 
and 2 HHT2) and 4 healthy controls (Supplementary Table 1). This pilot study suggests that 
miRNAs belonging to the miR-23a-27a-24-2 cluster were more abundant in the plasma from 
HHT patients while miR-205 was less abundant in plasma from HHT patients compared to 
healthy controls. MiR-27a and miR-205 were chosen for validation, by qRT-PCR, in the 
plasma samples from a cohort of 24 HHT patients (11 HHT1 and 13 HHT2) and 16 healthy 
controls. Our data showed that miR-27a level was significantly elevated in HHT patient 
plasma samples (p=0.021) (Figure 1A). Conversely, miR-205 level was significantly lower in 
plasma samples of HHT patients compared to healthy controls (p=0.006) (Figure 1B). We did 
not observe any significant differences between HHT1 and HHT2 patients for miR-27a, and 
miR-205. Receiver operating characteristic (ROC) curve analysis, a plot of the true positive 
rate against the false positive rate for the different possible cutoff values of a diagnostic test, 
showed that circulating miR-27a and miR-205 levels were of significant diagnostic value for 
HHT patients. Mir-27a and miR-205 yield an area under the curve (AUC) of 0.76 (Figure 1C) 
and 0.79 respectively (Figure 1D). Taken together miR-27a and miR-205 (ratio miR-
27a/miR-205) yield an AUC of 0.87 (Figure 1E).  
 
MiR-205 impairs angiogenesis 
Since endothelial cells are the primary cellular targets of HHT, we investigated the 
effect of miR-205 on endothelial cell function by overexpressing miR-205 and evaluating the 
impact of this ectopic expression on the endothelial proliferation, migration and tube 
formation. Over-expression obtained by transfection of pre-miR-205 (Figure 2A) significantly 
decreased the proliferation of HUVECs compared to cells transfected with a pre-miR-control 
(Figure 2B). In order to investigate whether miR-205 affects endothelial cell migration, 
another crucial step of angiogenesis, we performed a wound closure assay, which showed that 
increasing miR-205 level reduced endothelial cell capacity to close the scratch (Figure 2C). 
The role of miR-205 as a modulator of endothelial cell organization into tubes was next 
evaluated. When seeded onto Matrigel
TM
, HUVECs develop into a capillary-like vessel 
network. Increasing levels of miR-205 in HUVECs reduced vascular network formation, as 
revealed by a lower number in tube branching (Figure 2D-E). To investigate the phenotypic 
effect of a reduced level of miR-205 in endothelial cell, HUVECs were transfected with anti-
miR-205. Blockade of miR-205 increased HUVECs proliferation (Figure 2F), migration 
(Figure 2G) and tubulogenesis (Figure 2H) compared to cells transfected with control anti-
miR. 
 
MiR-205 alters TGF- β signaling in endothelial cells 
TGF-β signaling is the main pathway affected in HHT endothelial cells. As 
endothelial cells express two types of TGF-β type I receptors, ALK5 and ALK1/ACVRL1, 
the influence of miR-205 on both pathways was first investigated by measuring, by qRT-
PCR, the RNA expression levels of two downstream targets of each pathways: ID-1 whose 
expression is under the control of the TGF- β/ALK1/Smad1/5/8 pathway and PAI-1 whose 
expression is under the control of the TGF- β/ALK5/Smad2/3 pathway [5,13,14].  
Over-expression of miR-205 by pre-miR-205 transfection in HUVECs resulted in a 
significant reduction of ID-1 (Figure 3A) and a significant increase of PAI-1 mRNA levels 
(Figure 3B). These results suggest that both TGF-β pathways are affected by miR-205 
expression in opposite directions: the TGF- β/ALK1/Smad1/5/8 pathway, whose target is ID1, 
is repressed, while the TGF-β/ALK5/Smad2/3 pathway, targeting PAI-1, is stimulated. To 
further confirm these results, we analyzed the impact of miR-205 over-expression in assay 
reporters of the activation of the ALK1/Smad1/5/8 (BRE-Luc reporter) and of the 
ALK5/Smad2/3 pathway (CAGA-Luc reporter) [15]. Consistent with the results described 
above, over-expression of miR-205 led to a lower activation of the BRE-Luc reporter (Figure 
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3C) while the CAGA-Luc reporter activity was increased (Figure 3C). These data confirm 
that miR-205 affects both TGF-β pathways, in an opposite manner, displacing the TGF-β 
balance in EC towards the anti-angiogenic side.  
 
MiR-205 targets Smad1 and Smad4 
In order to unravel the mechanism by which miR-205 affects the TGF-β pathway, we 
decided to investigate the regulation of two predicted targets of miR-205, namely Smad1 and 
Smad4 (Targetscan, Figure 4A). These two proteins play a key role in the TGF-β pathway. 
Over-expression of miR-205 did not significantly affect Smad1 and Smad4 (Figure 4B) at the 
mRNA level. However, we observed a drastic reduction of Smad1 and Smad4 (Figure 4C) at 
the protein level by miR-205 over-expression. Similarly, inhibition of miR-205 using anti-
miR-205 did not significantly affect Smad1 and Smad4 mRNA levels (Figure 4D) while their 
protein levels increased (Figure 4E).  
To confirm that Smad1 and Smad4 are directly regulated by miR-205, we constructed 
luciferase reporter vectors encoding segments of the 3’UTR of Smad1 (human) and Smad4 
(human) (WT Smad1 3’UTR and WT Smad4 3’UTR), as well as a control vectors containing 
4 mismatches in the predicted miR-205 binding site (Mut Smad1 3’UTR and Mut Smad4 
3’UTR). Cotransfection of the Smad1 3’UTR plasmid with pre-miR-205 in HEK293T cells 
resulted in a significant decrease in the luciferase activity compared to cells cotransfected 
with the pre-miR-control. Over-expression of miR-205 did not decrease the luciferase activity 
in cells transfected with the mutated 3’UTR target sequence (Figure 4F). Similar results were 
obtained with the 3’UTR of Smad4 (Figure 4G) indicating that both Smad1 and Smad4 are 
direct targets of miR-205. 
 
TGF-β modulates MiR-27a and miR-205 in endothelial cells  
In order to test if the increased level of miR-27a and the reduced level of miR-205 
observed in patient plasmas could be due to a perturbation of the TGF- β pathway in 
endothelial cells, HUVECs were stimulated with low (1ng/ml) and high (10ng/ml) TGF-β 
concentrations before miRNA isolation. While the levels of miR-205 increased only after 
treatment with low TGF-β concentration, the levels of miR-27a significantly increased at 1 
and 10 ng/ml in a concentration dependent manner (Figure 5). 
 
 Discussion 
The newly discovered accessibility and stability of the circulating miRNAs have 
opened the way to new opportunities to screen and monitor a large variety of diseases non 
invasively [16-19]. Currently, molecular diagnosis of HHT involves sequencing of 
ACVRL1/ALK1 and ENG coding regions, large deletion/duplication analysis, and if no 
mutation is identified, analysis of Smad4 coding region. Still, approximately 15% of HHT 
cases have no mutations found in the coding regions of these three genes. Our study identified 
the miR-27a and miR-205 as new circulating biomarkers, which could help to a better 
screening of HHT patients. Our data show an elevated level of miR-27a and a reduced level 
of miR-205 circulating in plasma samples from HHT patients, compared to healthy controls. 
Interestingly, this observation is valid for both HHT1 and HHT2 patients suggesting that the 
regulation occurring at the level of miR-27a/205 is a common feature independently of the 
causal mutation of the disease. Further studies will be required to confirm these data including 
HHT patients with mutations in other genes than ENG and ACVRL1/ALK1.  
It is well established that HHT syndrome is due to alterations in angiogenesis and 
microvessel density [20]. A further study on Blood Outgrowth Endothelial Cells (BOECs) 
from HHT patients compared to those from control donors, reveals an HHT gene 
fingerprinting where a set of genes tightly related with angiogenesis was identified [21]. The 
increased levels of miR-27a (proangiogenic) [22,12] and the decreased levels of miR-205 
(antiangiogenic) are thus consistent with the altered angiogenesis observed in HHT patients 
due to endoglin or ALK1 haploinsufficiency and will open a new window for future therapies. 
Other plasma soluble components were previously identified as biomarkers of HHT as sEng 
and Ang-2 [23], but their lower levels in plasma seemed to be a result of the 
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haploinsuficiency in endoglin or ALK1 on endothelial cells. Since we show here that miR-
205, which is expressed in EC, impairs angiogenesis, we could speculate that miR-205 plays 
an endogenous role in modulating EC function. Consequently, miR-205 might thus not only 
be a marker of HHT but also a putative therapeutic target. Endoglin and ALK1 are 
predominantly expressed in endothelial cells and therefore these cells are the primary cellular 
targets of the disease. We thus hypothesize that the reduced levels of circulating miR-205 
reflects a lower miR-205 expression by the endothelial cells. However other cell targets such 
as smooth muscle, hematopoietic and endothelial precursor cells are also important to 
promote the lesion secondarily to an endothelial cell defect. Since mir-205 expression levels 
in endothelial cells are low (Ct value of 29) compared to other miRNAs previously described 
to play a role in endothelial cells such as miR-221 (Ct values 23) or miR-27a (Ct values of 
respectively 23 and 24), our study does not rule out that other cell types could participate in 
the secretion of the deregulated miRNAs in the circulation. In addition, it has been recently 
proposed that the transfer of microRNAs by exosomes could be a new mechanism of 
communication between cells [24-26]. Therefore, one can speculate that the reduced level of 
miR-205 in the plasma of HHT patients, even if primary caused by endothelial cells, could 
also affect the phenotype of other target cells. In addition, the mechanisms or miR-205 
regulation in EC remains to be elucidated.  
We showed in vitro that treatment of endothelial cells with low TGF-β concentration 
increased miR-205 level. Therefore, one possible mechanism would be that miR-205 
expression in endothelial cells is regulated by the TGF-β through the ALK1/Smad1/5/8 
pathway. As this pathway is reduced in the HHT patients, the resulting levels of miR-205 
would be decreased. On the other hand, miR-27a level is higher after treatment with TGF- β 
in a concentration dependent manner, starting induction at low concentration and reaching a 
maximum at high concentration. This is suggestive of a miR-27a expression mainly regulated 
through the TGF-β/ALK5/Smad2/3 pathway. In a way, both miRNAs, miR-27a and miR-205, 
are found in HHT patient’s plasmas according to the TGF-β pathways status of the endothelial 
cells. In fact, in HHT patients, the ALK1/Endoglin/Smad1/Smad4 pathway is decreased and 
the alternative ALK5/Smad2/3 pathway is favored. Therefore, the resulting level of miR-27a 
would be increased. 
The HHT mutations so far reported involve components of a common signal 
transduction pathway that is altered in HHT [27].  Endoglin is a co-receptor for multiple 
receptor complexes of the TGF-ß superfamily [28]. Endoglin interacts in endothelial cells 
with ALK-1, an endothelial-specific type I receptor that can associate with TGF-ß type II 
receptor (TGFßRII). Interestingly, TGFβRII in endothelial cells, can associate with two 
different TGF-ß type I receptors: TGFßRI (also known as ALK-5), or ALK-1[5]. ALK-1 and 
ALK-5 activate different Smad pathways, resulting in opposite endothelial cell responses in 
terms of pro- or anti-angiogenic gene expression [29,13,14,30].  TGF-β signaling through 
ALK1/Smad1/5/8 is pro-angiogenic, eliciting proliferation, migration and the transcription 
activation of target genes such as ID1. While signaling through ALK5/Smad2/3 activates 
target genes involved in the inhibition of proliferation, migration, matrix deposition, such as 
PAI-1 and processes associated with the endothelial cell quiescence. Moreover, a fine tuning 
on signaling and communication of both pathways is necessary. Thus, ALK5 contributes to a 
TGFβ-dependent recruitment of ALK1 to the receptor complex and is required for optimal 
ALK1 activation. Moreover, ENG recruitment to the TGF-βR2–ALK1–ALK5 receptor 
complex promotes signaling via the Smad1/5/8 pathway and this indirectly inhibits Smad2/3 
signaling via the ALK5/Smad2/3 pathway [5,13]. 
In the present work, we have described for the first time, that the miR-205 is 
downregulated in HHT patients and plays an anti-angiogenic role in endothelial cells. Indeed, 
miR-205 expression inhibits proliferation, migration and tube formation. We also show that 
miR-205, by its ability to target Smad1 and Smad4, plays in EC an important role in the 
angiogenesis regulation by the TGF-β signaling pathway. These two targets are known to 
form a heterodimer Smad 1/4 that is involved in the proangiogenic signaling pathway TGF-
β/ALK1/Smad1/5 controlling the transcription of ID-1. Overexpression of miR-205 in EC 
would then result in a reduced ALK1 signaling. We suggest that the balance would then be in 
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favor of ALK5 signaling (Figure 6). In favor with this view is the observed regulation on 
PAI-1/ID-1 expression: while ID-1 is downregulated upon miR-205 overexpression 
PAI-1 is upregulated. MiR-205 was first described as a blocker of the EMT transition [31]. 
Interestingly, miR-205 has also been reported as an inhibitor of the VEGF expression in 
tumor cells [32]. These data are important in the context of HHT since VEGF levels are 
elevated in the circulation of HHT patients. We can therefore suspect that the reduced levels 
of miR-205 could participate to the over-production of VEGF. This excess of VEGF 
combined with the decrease of miR-205 and the increase of miR-27a in HHT patients would 
promote an excessive and abnormal angiogenesis.  
Leaving aside the arteriovenous malformations which may be present in brain, liver, 
and lung, the rupture of which would lead to fatal haemorrhages in HHT patients, the more 
common and disabilitating problem is epistaxis. So far, attempts to treat epistaxis with 
pharmacological products have followed different strategies: 1) increasing the stability of the 
coagulation process with antifibrinolytics [21], (2) increasing the transcription of ENG and 
ALK1 promoters by SERMs like Raloxifene [33], the only orphan drug for the HHT so far 
designated, or (3) suppressing of excessive and abnormal angiogenesis through 
antiangiogenic agents such as Bevacizumab (recombinant full-length humanized antibody 
active against VEGF-A).  However, the currently available drugs can result in serious adverse 
events: frequent and unpredictable side effects for antiangiogenic strategies include 
thrombosis, hemorrhages, decreased wound healing, and organ perforation.  Therefore, 
alternative therapeutic options are required and therapies based in the correction of the 
decreased level of miR205 in HHT appears promising.  
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Material and Methods 
 
Cell culture and reagents 
Isolation and cultivation of human umbilical vein ECs (HUVEC, passages 6 to 11) 
were described previously [34]. 
 
Patients 
Peripheral venous blood samples were collected from all donors with EDTA as 
anticoagulant. Blood samples were centrifuged at 15,000 g for 15 min to obtain plasma, and 
samples were stored at -80ºC until analysis. Pilot study using miRNA PCR panels (Exiqon) 
was performed on 4 control and 4 HHT (2 HHT1 and 2 HHT2) patients.  A total of 24 HHT 
patient samples were evaluated by qRT-PCR; eleven of them were HHT1 and the remaining 
13 patients were HHT2.  miRNAs plasma levels were also assayed by qRT-PCR in 16 control 
subjects to establish the normal range. All HHT patients included in the present study were 
clinically diagnosed following the Curaçao criteria and their genetic mutations were identified 
by sequencing. Genetic characteristics and clinical manifestations are summarized in table 1. 
 
Transfection of pre-miR-205 and anti-miR-205 in HUVEC  
Pre-miR 205 and pre-miR-control (50 nM, Ambion) or Anti-miR-205 and Anti-miR-
control (25 nM, miRcurry LNA power inhibitor, Exiqon) were transfected into HUVECs with 
Dharmafect-4 (Dharmacon Research Inc) according to the manufacturer’s instructions. After 
transfection for 24 h, cells were washed and kept for additional 24 h in EGM-2 medium. 
Functional assays were performed as previously described below and in [35,36]. 
 
Cell proliferation.  
Transfected cells were plated in 96-well culture plates at a density of 3,000 cells per 
well in 100 µl of EBM-2 (Lonza) supplemented with 0.5 % serum (for Pre-miR) or EGM-2 
(for Anti-miR) and incubated for 72 h. Proliferation was analyzed 24 h later by measuring 
BrdU incorporation using the Cell Proliferation ELISA, BrdU (Colorimetric) (Roche).  
 
Scratch wound migration assay 
Transfected cells were plated in 48-well culture plates at a density of 50,000 cells per 
well in 300 µl of EGM-2 (Lonza) and incubated for 24 h to reach confluence. Using a tip, a 
wound was made in the monolayer (at time 0). The cells were then washed with PBS and 
incubated with EBM-2 medium containing 10 ng/ml recombinant bFGF (Promega Corp.) and 
50 ng/ml recombinant VEGFa (RELIATech GmbH) (for Pre-miR) or EBM-2 supplemented 
with 0,5 % serum (for Anti-miR) for 16 h. The distance between the two sides of the wound 
was measured with a graduated ocular lens coupled with an Olympus CKX41 microscope 
(Olympus). The distance between the two sides of the wound after 8 h of migration was 
subtracted from the distance at time 0 and represented on a graph. 
 
Capillary network formation on a Matrigel matrix 
Transfected cells were plated in 96-well culture plates pre-coated with 35 µl Matrigel 
per well (BD Biosciences) at a density of 10000 cells per well in 100 µl of EGM-2 (Lonza). 
The cells were incubated for 16 h. Pictures were taken with an Olympus microscope 
(Olympus). Quantitative analysis of network structure was performed with ImageJ software 
(http://rsbweb.nih.gov/ij/) by counting the number of intersections in the network and 
measuring the total length of the structures.  
 
Luciferase Assay (3'UTR reporter assays) 
 HEK293T cells were transfected with 30 pmol of pre-miR-Control or pre-miR-205 
with DharmaFECT-4 (Dharmacon Research Inc). The next day, cells were transfected with 25 
ng of the psiCHECK2 vector (Promega) encoding  segments of the 3’UTR of the human 
Smad1 (149 pb spanning the miR-205 seed match sequence) and human Smad4 (415pb 
spanning the miR-205 seed match sequence) or their mutated 3’UTR (4 mutations in the miR-
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205 predicted target site) with JET-PEI (Polyplus transfection) following manufacturer’s 
instructions. Wild-type region of 3’UTR human Smad1 and Smad4 mRNA binding seed 
sequences of miR-205 are respectively 5’-UGAAGAA-3’and 5’-AUGAAGGA-3’. Mutated 
region of 3’UTR human Smad1 and Smad4 mRNA binding seed sequences of miR-205 are 
respectively  5’-AGUACCAU-3’ and  5’-AGCAUGCA-3’. Forty-eight hours later, luciferase 
assay was performed using Dual-Luciferase Reporter Assay System (Promega). Renilla 
luciferase activity was normalized to Firefly luciferase. 
 
Luciferase Assay (promoter reporter assays). 
HUVEC cells were transfected with 30 pmol of pre-miR-Control or pre-miR-205 
with DharmaFECT-4 (Dharmacon Research Inc). The next day, cells were transfected with 25 
ng of the Bre-luC [15] and CAGA-Luc [37] vectors kindly provided by Dr P ten Dijke 
(Leiden University Medical Center, The Netherlands) with JET-PEI (Polyplus transfection) 
following manufacturer’s instructions.  Forty-eight hours later, luciferase assay was 
performed using Dual-Luciferase Reporter Assay System (Promega).  Firefly luciferase 
activity was normalized to Renilla luciferase. 
 
MicroRNA profiling in plasma 
Pilot study using miRNA PCR panels (Exiqon, human panel I, V2) was performed on 
4 controls and 4 HHT (2 HHT1 and 2 HHT2) patients.  RNA was extracted from plasma as 
previously described [26] and qRT-PCR was performed following manufacturer instructions. 
miRNAs of interest were selected based on their expression levels and differential regulation 
in control vs HHT patients. 
 
RNA extraction, miRNA expression analysis by TaqMan MicroRNA Assay and 
Quantitative Real-time PCR Analysis 
Total RNAs were extracted with the miRNeasy kit (Qiagen). Taqman methods were 
used to assess miRNA expression. Briefly, 10 ng RNA were reverse transcribed to cDNA 
with the Taqman microRNA Reverse Transcription kit and the Taqman microRNA assay 
stem loop primers (Applied Biosystems). Resulting cDNAs were used for quantitative real-
time PCR using Taqman microRNA assay and Taqman universal PCR master mix reagents 
(Applied Biosystems). Thermal cycling was performed on an Applied Biosystem 7900 HT 
detection system (Applied Biosysems). The relative miRNA levels were normalized to two 
internal controls, RNU-44 or RNU-48. For the plasma samples, the relative miRNA levels 
were normalized to two spikes-in miRNAs: cel-miR-39 and cel-miR-238 (Applied 
Biosystems).  
For mRNA expression analysis, RNAs were extracted with the miRNeasy kit 
(Qiagen) according to the manufacturer’s protocol. cDNA synthesis was performed with 1 µg 
total RNA and the iScript cDNA Synthesis Kit (Biorad) according to the manufacturer’s 
instructions. Resulting cDNAs (20 ng) were used for quantitative real-time PCR using the 
SYBR green method (Roche Applied Sciences). Thermal cycling was performed on an ABI 
Prism 7900 HT Sequence Detection System (Applied Biosystems). For all reactions, no-
template controls were run, and random RNA preparations were also subjected to sham 
reverse transcription to check for the absence of genomic DNA amplification. Quantitative 
real-time PCR was performed with SYBR green method (Bioline). Thermal cycling was 
performed on an Applied Biosystem 7900 HT detection system (Applied Biosysems). The 
relative transcript level of each gene was normalized to the housekeeping genes cyclophilin-A 
(PPIA), β-2 microglobulin (B2M). Primers (IDT-DNA) were designed using Primer Express 
software and selected to span exon-exon junctions to avoid detection of genomic DNA 
(primer sequences are provided below). 
hsa Smad1 for   CTCATGTCATTTACTGCCGTGT 
hsa Smad1 rev   TATTCGCTGTGTCTTGGAACC 
hsa Smad4 for   CTCATGTGATCTATGCCCGTC 
hsa Smad4 rev   AGGTGATACAACTCGTTCGTAGT 
hsa PAI1 for   ACGTGGTTTTCTCACCCTATGG  
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hsa PAI1 rev   CATGCCCTTGTCATCAATCTTG 
hsa Id1 for   CTGCTCTACGACATGAACGG 
hsa Id1 rev   GAAGGTCCCTGATGTAGTCGAT 
hsa B2M for   GAGTATGCCTGCCGTGT 
hsa B2M rev   AATCCAAATGCGGCATCT 
 
Preparation of cell extracts  
Cells were washed twice with cold PBS and scraped into lysis buffer (25 mM HEPES 
(pH 7.9), 150 mM NaCl, 0.5% Triton, 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonylfluoride) on ice. Insoluble cell debris was removed by centrifugation at 
10,000 g for 15 min. Aliquots of protein-containing supernatants were stored at -80°C. Protein 
concentrations were determined by the Bradford method, with the Bio-Rad protein assay 
reagent (Bio-Rad Laboratories).  
 
Western Blot Analysis 
Soluble cell lysate (30 μg) was resolved by SDS-PAGE (12%) and transferred to a 
polyvinylidene fluoride membrane (Milipore Corp.). Blots were blocked overnight and 
probed with primary antibodies: anti-Smad1 (D59F7, Cell Signaling Technology), anti-
Smad4 (sc-7966, Santa Cruz Biotechnology), and anti-β-tubulin (ab6046, Abcam). After 
washes with Tris-buffered saline containing 0.1% Tween 20, antigen-antibody complexes 
were detected with peroxidase-conjugated secondary antibody (Cell Signaling Technology) 
and an enhanced fluoro-chemiluminescent system (ECL; Pierce Biotechnology).  
 
Statistics 
 All values were expressed as means ± SD (or SEM for patient data). Comparisons 
between different conditions were assessed using the Student t-test. ). A P value of <0.05 was 
considered statistically significant. The plasma level of the different miRNA was used as the 
input to plot Receive Characteristics Curves (ROC). ROC curves are displayed as the true 
positive rate (Sensitivity) versus 1 minus the false positive rate (Sensibility). The area under 
the ROC curve (AUC) is a measure of discrimination accuracy. 
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Figures 
 
 
Fig. 1 HHT patients show altered levels of miR-27a and miR-205 
Levels of miR-27a (a) and miR-205 (b) were measured in plasma samples of a total of 24 
HHT patients (HHT1 (n=11) and HHT2 (n=13)) and in 16 healthy controls by TaqMan qRT-
PCR. Data are expressed as relative miRNA levels normalized to two spikes-in C.elegans 
miRNAs and are expressed as means ± SEM. * P<0.05 vs. healthy patients. ROC curve 
representing the sensitivity and the specificity of miR-27a (c) and miR-205 (d) to discriminate 
between healthy controls (n=16) and HHT patients (n=24). (E) ROC curve obtained by using 
the ration between miR-27a and miR-205 to discriminate between control (n=16) and HHT 
patients (n=24). 
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Fig. 2 Modulation of MiR-205 level impairs endothelial cell proliferation, migration and 
tube formation 
a) Expression level of miR-205 in HUVECs transfected with pre-miR-control and pre-miR-
205 by qRT-PCR. HUVECs were transfected with pre-miR-control and pre-miR-205 before 
(b) their proliferation status was measured by measuring the amount of incorporated BrdU (c) 
their relative migration in a scratch assay was measured and (d) before being seeded in 
matrigel to determine their ability to form tube like structures. (e) Representative picture of 
HUVECs tubulogenesis after being transfected with pre-mir-Control and pre-miR-205. 
HUVECs were transfected with anti-miR-control and anti-miR-205 before measuring their (f) 
proliferation status, (g) migration and (h) ability to form tube-like structures. Data are 
expressed as means ± SD. * P<0.05 vs. respective control. n≥3. 
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Fig. 3 MiR-205 favors ALK5 pathway in endothelial cells 
qRT-PCR expression analysis of ID-1 (a) and PAI-1 (b) in HUVECs transfected with pre-
miR-control and pre-miR-205. Luciferase activity in HEK293 cells transfected with (c) a 
BRE-LUC construct (Smad1/5-ALK1 reporter) or (d) a CAGA-LUC construct (Smad 2/3-
ALK5 reporter) and transfected with pre-miR-control and pre-miR-205. All values are 
expressed as mean ± SD, n≥3. * P<0.05 vs. corresponding control. 
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Fig. 4 MiR-205 targets Smad4 and Smad1 in endothelial cells 
(a) Focus on the pairing sequences of Smad1 and Smad4 3’UTR and miR-205 in human. 
qRT-PCR expression levels of Smad1  and Smad4 (b) in HUVECs transfected with pre-miR-
control and pre-miR-205. n≥3, no significant difference. Protein levels (Western blot) of 
Smad1 and Smad4 (c) in total protein extracts from HUVECs transfected with pre-miR-
control and pre-miR-205. qRT-PCR expression levels (d) and protein levels (Western blot) 
(e) of Smad1 and Smad4 from HUVECs transfected with anti-miR-control and anti-miR-205. 
Luciferase activity from Smad1  3’UTR (f) and Smad4 3’UTR (g) WT and mutated reporter 
plasmid and the cotransfected into HEK293T cells with pre-miR-control or pre-miR-146a. 
Data are means ± SD (n≥3).* P<0.05 vs. corresponding pre-miR-control. 
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Fig. 5 TGF- modulates miR27-a and miR-205 expression. 
 Level of miR-27a (a) and mir-205 (b) in HUVECs treated 24 hours with TGF-.  All values 
are expressed as mean ± SD, n≥3. * P<0.05 vs. corresponding control. 
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Fig. 6 Mir-205 levels contribute to modulate the equilibrium between proliferation 
(angiogenesis) and quiescence (deposition of extracellular matrix) in the endothelium by 
regulating the TGF-β pathway. (a) Proposed equilibrium in normal endothelial cells of both 
TGF-β induced pathways dependent on different type I receptors ALK5 and ALK1. Under 
normal conditions miR-205 downregulates the levels of Smad1 and Smad 4. This situation is 
marked in the figure by the interruption bar for miR-205 over the targets Smad1 and 
Smad4.(b) In HHT patients, the lower levels of miR-205 would favor the signaling through 
Smad1, although this pathway is partially inactivated by the ALK1 or Endoglin 
haploinsufficiency, derived of the disease. The partial recovery of Smad1 and Smad4 levels is 
shown by the arrows. 
 
